Navigation Links
Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study
Date:7/24/2008

ion on Bioheart, visit http://www.bioheartinc.com.

Footnotes:

(1) MARVEL: A Phase II/III, Double-Blind, Randomized, Placebo-Controlled Multi-center study to Assess the Safety and Cardiovascular Effects of MyoCell Implantation by a Catheter Delivery System in Congestive Heart Failure Patients Post-Myocardial Infarction(s)

(2) The MYOSTAR(TM) Injection Catheter is not available for sale in the U.S. It is in use in IND investigations

MyoCell and MyoCell SDF-1 are trademarks of Bioheart, Inc.

MyoStar and NOGA XP are trademarks of Cordis Corporation, a Johnson & Johnson company

Forward Looking Statements:

Except for historical matters contained herein, statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Without limiting the generality of the foregoing, words such as "may", "will", "to", "plan", "expect", "believe", "anticipate", "intend", "could", "would", "estimate", or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Investors and others are cautioned that a variety of factors, including certain risks, may affect our business and cause actual results to differ materially from those set forth in the forward-looking statements. These risk factors include, without limitation, (i) our ability to secure additional financing; (ii) the timely success and completion of our clinical trials; (iii) the occurrence of any unacceptable side effects during or after preclinical and clinical testing of our product candidates; (iv) regulatory approval of our product candidates; (v) our dependence on the success of our lead product candidate; (vi) our inability to predict the extent of our future losses or if or when we will become profitable; (vii) our ability to protect our intellect
'/>"/>

SOURCE Bioheart, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
2. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
3. Bradmer reports progression free survival data from previous Phase II glioblastoma multiforme trials
4. GeoVax Reports Progress on Its AIDS Vaccine Technology
5. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
6. MAP Pharmaceuticals Reports Positive Pharmacological Response Data for Migraine Product Candidate at the American Headache Society Annual Meeting
7. Alimera Reports Results From the Three-Month Interim Readout of the Human PK Medidur(TM) FA Study
8. Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing
9. Victory Pharma, Inc. Reports MGX006 Enters Into Pivotal Development Program
10. Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus
11. Synvista Therapeutics Reports Results of Three Phase 2 Clinical Trials of SYI-2074 in Diabetic Patients with Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2008)...RNewswire-FirstCall/ -- CEL-SCI Corporation,(NYSE:... Material Transfer,Agreement (MTA) with the Nation...d the laboratory of Dr. Francesco M. Marincola, M....to the tumor microenvironment,caused by CEL-SCI,s ...of,the Infectious Disease and Immunogentics Sectio...
(Date:10/7/2008)...Today at ACG Annual Scientific Meeting -, ORLANDO...Pharmaceuticals, Inc. (formerly Microbia, Inc.) an...nounced the presentation of results from a Phase,2...y in 420 patients with,irritable bowel syndrome wi...cates that once- daily oral dosing of linaclotide,...
(Date:10/7/2008)...lighting CIMZIA,s long-term benefits and value in,...ted at American College,of Gastroenterology (ACG),...ata from two studies,presented this week by UCB at...nual Meeting demonstrate that CIMZIA(R) (certolizu...mor Necrosis Factor alpha) - provides,sustained im...
(Date:10/7/2008)...rt Enrolled in Stage A of Trial Assessing Regimen ...and Paclitaxel -, TUSTIN, Calif., Oct. 7 /PRNewsw...(Nasdaq: PPHM ), a clinical stage biopharmaceutic...e treatment of cancer and,hepatitis C virus (HCV) ...nrollment in the first stage of a Phase II trial o...
Breaking Medicine Technology:CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect 2CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect 3Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 2Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 3Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 4Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 5CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 2CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 3CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 4CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 5CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 6CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 7CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 8CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 9Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 2Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 3Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial 4deCODE Files IND for DG071 a Novel PDE4 Modulator Being Developed for Alzheimers and Other Cognitive Disorders 3205 1deCODE Files IND for DG071 a Novel PDE4 Modulator Being Developed for Alzheimers and Other Cognitive Disorders 3205 2deCODE Files IND for DG071 a Novel PDE4 Modulator Being Developed for Alzheimers and Other Cognitive Disorders 3205 3deCODE Files IND for DG071 a Novel PDE4 Modulator Being Developed for Alzheimers and Other Cognitive Disorders 3205 4deCODE Files IND for DG071 a Novel PDE4 Modulator Being Developed for Alzheimers and Other Cognitive Disorders 3205 5So called sandfish could help materials handling and process technology specialists 5204 1So called sandfish could help materials handling and process technology specialists 5204 2So called sandfish could help materials handling and process technology specialists 5204 3Brown University and Women 26amp 3B Infants Hospital expand national childrens study to Bristol County 5202 1Brown University and Women 26amp 3B Infants Hospital expand national childrens study to Bristol County 5202 2Brown University and Women 26amp 3B Infants Hospital expand national childrens study to Bristol County 5202 3Brown University and Women 26amp 3B Infants Hospital expand national childrens study to Bristol County 5202 4Isolagen to Present at the JMP Securities Healthcare Focus Conference 8074 1Isolagen to Present at the JMP Securities Healthcare Focus Conference 8074 2
...0, 2007 - Australian,biotechnology company Avexa (... from its Phase IIb trial for apricitabine (ATC).,...ase inhibitor,(NRTI) being developed for the treat...ant HIV., The Phase IIb trial compared the effecti...ts with drug-resistant HIV with,the effectiveness ...
.../ -- Treatment of,coronary artery disease (CAD) ap...ng, according to a study published today in The,Am...on rates for heart attacks (acute myocardial,infar...ossibly due,to broader use of preventive treatment...lines in risk factors like smoking. , The study is...
Other Medicine Technology:Avexa Reports Positive Phase IIb Result 2Avexa Reports Positive Phase IIb Result 3Avexa Reports Positive Phase IIb Result 4Hospitalization Rates for Coronary Artery Disease Decline in the,U.S. 2Hospitalization Rates for Coronary Artery Disease Decline in the,U.S. 3
(Date:10/7/2008)...RNewswire-FirstCall/ -- Stallergenes S.A.,today an...greement with,Catalent for the promotion and distr...FLEX(R), co-developed and co-manufactured by Catal...sts of a syringe pre-filled with adrenaline, which....3 and 0.15 mg), in an,autoinjector device. The Me...
(Date:10/7/2008)...of asthma in a young child may well be more challe..., according to a review of research and clinical e... Indiana University School of Medicine and Riley H... issue of Clinical Pediatrics . , "Wheezing ca... Professor of Pediatrics at the IU School of Medic...
(Date:10/7/2008)...rial Specialties, Mfg. is pleased to announce the ...hese filters are exclusively available from Indust... push-to-connect style fittings integrated into th...ne filter offers versatility and customization for... (PRWEB) October 7, 2008 -- Exclusively availa...
(Date:10/6/2008)...fight against childhood obesity, researcher notes ... Three-quarters of middle schools have vending mac...new study finds. , The research demonstrates th...ls, and "that those vending machines don,t always ...y Virus, a registered dietitian with the Center fo...
Breaking Medicine News(10 mins):Health News:Stallergenes Partners With Catalent and the Medical House for Commercialization of Adrenaline Autoinjector in Europe 2Health News:Wheezing and asthma in young children 2Health News:Vending Machines Found in Most Middle Schools 2
...ing to recent update, people with type 2 diabetes ...emia) may be able to safely reduce their risk for ...ase niacin.// The finding runs counter to previous... blood sugar levels in diabetics. Certain studies,...
...ing to researchers, low body temperature, low insu...be linked to a slowdown of the aging process. It i...ses the lifespan of animals. Now researchers at th... about slowing down the aging process. They compar...
...ing to a new study, hospitals staffed with more re...- save more lives from deadly complications, and r...ify worries about the nation's growing nursing sho...s because we don't have the knowledge of the regis...
...study contributes to the findings of liver cancer....of Medicine report findings on a potential new tre...archers injected a compound called 3-bromopyruvate...cerous tumor. They say it did not adversely affect...
Other Medicine News:Health News:Nurses save more lives 2
Lorenz 2.0 mm titanium system for the midface provides an excellent alternative to lower profile systems in areas of the midface where greater fixation is needed.
The Neuroclip is designed for safe, quick, and stable fixation of cranial bone flaps. Application is simple with minimal instrumentation. The Neuroclip can be applied to the cranial bone flap while t
Lorenz 1.0 mm titanium system provides a rigid fixation alternative for areas with high palpability and prominent bone formation. These areas include the frontal bone and the areas surrounding the or
1.0 mm Micro System. The Titanium Micro System is also useful in the practice of ENT, Neurosurgery and Handsurgery.
Medicine Products: